Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | LA |
swelling at injection site; redness at the injections site; pain at the injection site; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On 17-MAR-2025, the patient received the 1st dose of Shingrix (left arm). On 17-MAR-2023, an unknown time after receiving Shingrix, the patient experienced injection site erythema (Verbatim: redness at the injections site) and injection site pain (Verbatim: pain at the injection site). On 17-MAR-2025, the patient experienced injection site swelling (Verbatim: swelling at injection site). On 20-MAR-2023, the outcome of the injection site erythema and injection site pain were resolved (duration 3 days). On 20-MAR-2025, the outcome of the injection site swelling was resolved (duration 3 days). It was unknown if the reporter considered the injection site swelling, injection site erythema and injection site pain to be related to Shingrix. It was unknown if the company considered the injection site swelling, injection site erythema and injection site pain to be related to Shingrix. Additional Information: GSK receipt date: 03-APR-2025 The patient reported that after receiving the 1st dose of Shingrix vaccine he experienced pain, swelling, redness at the injection site for 4 days then was completely recovered. The batch number and expiry date of Shingles vaccine were unknown.